LAUSR

In the past decade, the effect of curcumin or turmeric supplementation on many aspects of health status in different populations has been evaluated. In the present study, a systematic review and meta‐analysis were conducted to estimate the effect of curcumin administration on inflammatory markers in hemodialysis (HD) patients. A systematic search was performed in MEDLINE, EMBASE, Scopus, and Clarivate Analytics Web of Science databases from 1997 until June2022 for terms related to curcumin/turmeric and hemodialysis (HD). Randomized, double‐blind/single‐blind studies examining the effects of curcumin/turmeric on the inflammation of HD participants older than 18 years were considered eligible for inclusion. Data were pooled using the weighted mean difference (WMD) and 95% CI as the summary statistic, considering a random‐effects analysis model. The data that were pooled from nine studies with 472 patients indicated that curcumin‐containing supplement had significant effect on serum C‐reactive protein (CRP) levels (WMD = −3.3 mg/L; 95% CI: −5.4 to −1.3; p < 0.001, I2 = 76.7%, 8 studies, 467 participants), and interlukine‐6 (IL‐6) levels (SMD: −0.4; 95% CI: −0.8 to −0.07; p = 0.02, I2 = 31.6%, 3 studies, 153 participants) compared control group. Although curcumin intervention could not change tumor neurosis factor‐α (TNF‐α) concentration (SMD = −0.3; 95% CI: −0.7 to 0.04; p = 0.08, I2 = 25.3%, 3 studies, 153 participants), when compared with the placebo group. Our study's main limitations were small number of studies, overall high risk of bias in the included trials, and high heterogeneity in some results. The present meta‐analysis suggested that intervention with curcumin‐containing supplements was associated with a significant reduction in serum hs‐CRP and IL‐6 concentrations in HD patients. The curcumin intervention in the reduction of hs‐CRP levels was greater than the minimal clinically important difference (MCID) for CRP (0.5 mg/L), which can be helpful in physicians' clinical decisions.